Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $60.6 million.

  • Cardiff Oncology's Cash & Equivalents rose 502.6% to $60.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.6 million, marking a year-over-year increase of 502.6%. This contributed to the annual value of $51.5 million for FY2024, which is 13768.18% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Cash & Equivalents is $60.6 million, which was up 502.6% from $71.0 million recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Cash & Equivalents peaked at $79.9 million during Q1 2025, and registered a low of $10.6 million during Q2 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $19.4 million (2023), whereas its average is $29.6 million.
  • In the last 5 years, Cardiff Oncology's Cash & Equivalents tumbled by 9088.19% in 2021 and then soared by 32823.45% in 2025.
  • Over the past 5 years, Cardiff Oncology's Cash & Equivalents (Quarter) stood at $11.9 million in 2021, then skyrocketed by 36.88% to $16.3 million in 2022, then surged by 32.47% to $21.7 million in 2023, then skyrocketed by 137.68% to $51.5 million in 2024, then rose by 17.74% to $60.6 million in 2025.
  • Its Cash & Equivalents stands at $60.6 million for Q3 2025, versus $71.0 million for Q2 2025 and $79.9 million for Q1 2025.